Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8356 to 8370 of 8987 results

  1. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued Reference number: GID-TA10697

    Technology appraisal guidance
    Discontinued

  2. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued Reference number: GID-TA10539

    Technology appraisal guidance
    Discontinued

  3. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued Reference number: GID-TA10570

    Technology appraisal guidance
    Discontinued

  4. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued Reference number: GID-TA10763

    Technology appraisal guidance
    Discontinued

  5. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued Reference number: GID-TA11207

    Technology appraisal guidance
    Discontinued

  6. Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]

    Discontinued Reference number: GID-TA11205

    Technology appraisal guidance
    Discontinued

  7. Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]

    Discontinued Reference number: GID-TA10857

    Technology appraisal guidance
    Discontinued

  8. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued Reference number: GID-TA10922

    Technology appraisal guidance
    Discontinued

  9. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued Reference number: GID-TA10236

    Technology appraisal guidance
    Discontinued

  10. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued Reference number: GID-MT536

    Medical technologies guidance
    Discontinued

  11. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

    Interventional procedures guidance
    Discontinued

  12. Belatacept for the prevention of organ rejection in kidney transplantation [ID87]

    Discontinued Reference number: GID-TAG239

    Technology appraisal guidance
    Discontinued

  13. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued Reference number: GID-TAG511

    Technology appraisal guidance
    Discontinued

  14. Microthane implants for breast reconstruction or breast augmentation (discontinued)

    Discontinued Reference number: GID-MT267

    Medical technologies guidance
    Discontinued

  15. Diagnostic services

    Discontinued Reference number: GID-CGWAVE0773

    NICE guideline
    Discontinued